CoChat

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 2 of the 40 sources its claims cite were checked for support.

Abstract

Context: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate system controlling fluid and hemodynamic homeostasis through vascular tonus and diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a decrease in particular MR-proANP. Objective: To investigate if treatment with liraglutide in women with PCOS reduces levels of the cardiovascular biomarkers MR-proADM, MR-proANP and copeptin. Methods: Seventy-two overweight women with PCOS were treated with 1.8 mg/day liraglutide or placebo for 26 weeks in a placebo-controlled RCT. Biomarkers, anthropometrics, insulin resistance, body composition (DXA) and visceral fat (MRI) were examined. Results: Baseline median (IQR) levels were as follows: MR-proADM 0.52 (0.45–0.56) nmol/L, MR-proANP 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: MR-proADM −6% (−11 to 2, P = 0.058), MR-proANP −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64). Reduction in MR-proANP concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group. Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in MR-proANP to be independently correlated with an increase in the heart rate. Conclusion: In an RCT, liraglutide treatment in women with PCOS reduced levels of the cardiovascular risk biomarkers MR-proANP with 25% and MR-proADM with 6% (borderline significance) compared with placebo. The decrease in MR-proANP was independently associated with an increase in the heart rate.

Overview

CoChat Summary

TL;DR

In a 26-week placebo-controlled RCT in overweight women with PCOS, liraglutide reduced MR-proANP by 25% and showed a borderline 6% reduction in MR-proADM, with no change in copeptin. The MR-proANP reduction was independently associated with an increase in heart rate.

Key findings

  • Baseline median (IQR) biomarker levels were MR-proADM 0.52 (0.45–0.56) nmol/L, MR-proANP 44.8 (34.6–56.7) pmol/L, and copeptin 4.95 (3.50–6.50) pmol/L.
  • After treatment, mean percentage differences between liraglutide and placebo were MR-proADM −6% (95% CI −11 to 2, P = 0.058; table P = 0.057), MR-proANP −25% (95% CI −37 to −11, P = 0.001), and copeptin +4% (95% CI −13 to 25, P = 0.64).
  • In the liraglutide group, ΔMR-proANP correlated inversely with Δheart rate (β −0.69, r 0.33, P = 0.03) and Δdiastolic blood pressure (β −0.89, r 0.34, P = 0.03); multiple regression adjusting for BMI, free testosterone, Matsuda index, VAT, heart rate, and eGFR showed ΔMR-proANP remained independently correlated with Δheart rate (β −0.77, s.e. 0.36, P = 0.045).
  • Liraglutide treatment increased heart rate by 6 bpm (95% CI 2–10, P = 0.006) and reduced weight by 5.2 kg (95% CI 3.0–7.5, P < 0.001) versus placebo.

Methods

  • Double-blind, placebo-controlled RCT (LIPT study): 72 overweight women with PCOS randomized 2:1 to 1.8 mg/day liraglutide or placebo for 26 weeks; inclusion required PCOS by Rotterdam criteria, BMI >25 kg/m² and/or insulin resistance, and non-hormonal contraception.
  • Biomarkers MR-proADM, MR-proANP, and copeptin were measured by automated immunofluorescence assay; anthropometrics, DXA body composition, MRI visceral/subcutaneous fat, insulin resistance indices, and routine biochemistry were also assessed.
  • A mixed model with repeated statement tested treatment-group differences over time; linear univariate and multiple regression analyses examined Δ biomarker associations in the liraglutide group.

Limitations

  • The paper states that 24-h ambulatory blood pressure and heart rate recordings were not performed, which would have given more precise estimates.
  • The paper states that the study may be underpowered for MR-proADM because the expected change was not met, and that biological/analytical variation means the small observed changes are less than suggested clinically relevant percent changes, weakening the results.
  • The paper notes that natriuresis was not measured, and that BNP, galectin-3, and troponins were not measured; the text also makes evident that the cohort was relatively young and without overt CVD, which may limit detection of subclinical changes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1530/ec-17-0327

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CONSORT flow.
Figure 1 CONSORT flow.CC BY-NC-ND · PubMed Central
Figure 2 Effect of liraglutide or placebo treatment on levels of MR-pro-adrenomedullin, copeptin, and MR-proANP. Median and interquartile range before and after 26 weeks of treatment.
Figure 2 Effect of liraglutide or placebo treatment on levels of MR-pro-adrenomedullin, copeptin, and MR-proANP. Median and interquartile range before and after 26 weeks of treatment.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

2 Valid · 0 Not valid · 27 Not checked · 34 Own results and interpretations

26 more claims

Create a free account to see all 63 claims and to verify the 38 references still open.

See all claims — free account
  • Probably not a substantial claim. 25
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 46 references

Research works printed but not linked: 44

  1. 2013, Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome, Journal of Clinical Endocrinology and Metabolism, 98, 4882, 10.1210/jc.2013-2141 · DOI · Paper page
  2. 2017, Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial, Diabetes, Obesity and Metabolism, 19, 901, 10.1111/dom.12884 · DOI · Paper page
  3. 2014, Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men, Diabetic Medicine, 31, 728, 10.1111/dme.12411 · DOI · Paper page
  4. 2015, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats, Diabetologia, 58, 1081, 10.1007/s00125-015-3496-9 · DOI · Paper page
  5. 2012, Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study, Fertility and Sterility, 97, 489, 10.1016/j.fertnstert.2011.11.001 · DOI · Paper page
  6. 2013, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis., BMJ Open, 3, e001986, 10.1136/bmjopen-2012-001986 · DOI · Paper page
  7. 2015, Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome, European Journal of Obstetrics and Gynecology and Reproductive Biology, 189, 19, 10.1016/j.ejogrb.2015.03.006 · DOI · Paper page
  8. copeptin a unifying factor behind the metabolic syndrome of and https org, Plasma Journal Clinical Endocrinology Metabolism, 201196, 10.1210/jc.2010-2981 · DOI · Paper page
  9. 2004, Use and abuse of HOMA modeling, Diabetes Care, 27, 1487, 10.2337/diacare.27.6.1487 · DOI · Paper page
  10. 2015, Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients, Journal of Hypertension, 33, 1458, 10.1097/hjh.0000000000000573 · DOI · Paper page
  11. 2016, A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries, Archives of Gynecology and Obstetrics, 293, 509, 10.1007/s00404-015-3976-7 · DOI · Paper page
  12. 2016, Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes, Obesity, 24, 820, 10.1002/oby.21418 · DOI · Paper page
  13. 2005, Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay, Clinical Chemistry, 51, 1823, 10.1373/clinchem.2005.051110 · DOI · Paper page
  14. 2011, Influence of sex and hormone status on circulating natriuretic peptides, Journal of the American College of Cardiology, 58, 618, 10.1016/j.jacc.2011.03.042 · DOI · Paper page
  15. 2016, Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis., Oncotarget, 7, 33715, 10.18632/oncotarget.9553 · DOI · Paper page
  16. 2014, Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity, BMC Obesity, 1, 24, 10.1186/s40608-014-0024-2 · DOI · Paper page
  17. 2004, Impact of obesity on plasma natriuretic peptide levels, Circulation, 109, 594, 10.1161/01.cir.0000112582.16683.ea · DOI · Paper page
  18. 2000, Adrenomedullin, a multifunctional regulatory peptide, Endocrine Reviews, 21, 138
  19. 2015, The LIPT-Study: on risk markers of vascular thrombosis in polycystic ovary syndrome a randomized, double-blind, placebo-controlled study of the effect of liraglutide, Journal of Obesity and Weight Loss Therapy, 5, 254
  20. 2014, Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome, Journal of Ovarian Research, 7, 31, 10.1186/1757-2215-7-31 · DOI · Paper page
  21. 2015, Serum copeptin, pentraxin 3, anti-mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome, Journal of Clinical Medicine Research, 7, 989, 10.14740/jocmr2375w · DOI · Paper page
  22. 2013, GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure, Nature Medicine, 19, 567, 10.1038/nm.3128 · DOI · Paper page
  23. 2005, Acute hyperinsulinemia is associated with increased plasma adrenomedullin concentrations in uncomplicated obesity, Experimental and Clinical Endocrinology and Diabetes, 113, 171, 10.1055/s-2005-837519 · DOI · Paper page
  24. 2009, Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery., Obesity, 17, 1184, 10.1038/oby.2009.22 · DOI · Paper page
  25. 2006, Plasma adrenomedullin levels in patients with polycystic ovary syndrome, Fertility and Sterility, 86, 942, 10.1016/j.fertnstert.2006.02.119 · DOI · Paper page
  26. 2017, Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential, Endocrine Connections, 6, 89, 10.1530/ec-16-0113 · DOI · Paper page
  27. 2013, Midregional pro-atrial natriuretic peptide in the general population/insights from the Gutenberg Health Study, Clinical Chemistry and Laboratory Medicine, 51, 1125
  28. 2014, Adrenomedullin and diabetes, World Journal of Diabetes, 5, 364, 10.4239/wjd.v5.i3.364 · DOI · Paper page
  29. 2015, Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment, Diabetic Medicine, 32, 343, 10.1111/dme.12594 · DOI · Paper page
  30. 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
  31. 2012, Adrenomedullin: possible predictor of insulin resistance in women with polycystic ovary syndrome, Journal of Endocrinological Investigation, 35, 553
  32. 2007, Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues, Peptides, 28, 1129, 10.1016/j.peptides.2007.03.005 · DOI · Paper page
  33. 2014, Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males, Endocrine Connections, 3, 11, 10.1530/ec-13-0087 · DOI · Paper page
  34. 2016, Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study, Gynecological Endocrinology, 33, 30
  35. 2016, Impaired atrial natriuretic peptide-mediated lipolysis in obesity, International Journal of Obesity, 40, 714, 10.1038/ijo.2015.222 · DOI
  36. 2010, Plasma copeptin and the risk of diabetes mellitus, Circulation, 121, 2102, 10.1161/circulationaha.109.909663 · DOI · Paper page
  37. 2006, Expression of adrenomedullin in adipose tissue of lean and obese women, European Journal of Endocrinology, 155, 177, 10.1530/eje.1.02170 · DOI
  38. 2015, Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes, Diabetes Care, 38, 132, 10.2337/dc14-1958 · DOI · Paper page
  39. 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, New England Journal of Medicine, 375, 311, 10.1056/nejmoa1603827 · DOI · Paper page
  40. 2016, Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial, Diabetes, Obesity and Metabolism, 18, 581, 10.1111/dom.12651 · DOI · Paper page
  41. 2013, Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy, Current Heart Failure Reports, 10, 434, 10.1007/s11897-013-0156-6 · DOI · Paper page
  42. 2014, Natriuretic peptides in cardiometabolic regulation and disease, Nature Reviews Cardiology, 11, 403, 10.1038/nrcardio.2014.64 · DOI · Paper page
  43. 2012, Adrenomedullin and cardiovascular diseases, JRSM Cardiovascular Disease, 1
  44. 2014, GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody, Endocrinology, 155, 1280, 10.1210/en.2013-1934 · DOI · Paper page

Cited by

See all 40

Metadata

Authors
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J.
Affiliations
University of Copenhagen (DK)
Corresponding author
Frøssing, Signe
Venue
Endocrine Connections
Published
2018-01
Volume
7
Issue
1
Pages
115-123
ISSN
2049-3614 (ISSN-L)
OpenAlex
W2781586249
Cited by
38
References
46
Citations by year
2026: 5 · 2025: 6 · 2024: 10 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 1
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • Endocrine Connections (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, polycystic ovary syndrome, atrial natriuretic peptide, adrenomedullin, copeptin, cardiovascular risk markers, GLP-1 receptor agonists, heart rate, diastolic blood pressure, insulin resistance, visceral fat, cardiovascular risk, overweight women, type 2 diabetes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. https://app.cochat.ai/papers/10.1530/ec-17-0327
The paper
Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018). Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocrine Connections. https://doi.org/10.1530/ec-17-0327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.